<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03887728</url>
  </required_header>
  <id_info>
    <org_study_id>1901-ABU-002-BL</org_study_id>
    <nct_id>NCT03887728</nct_id>
  </id_info>
  <brief_title>Comparison of Blood Flow in the Arteriae Uterinae in Ovarian Stimulation Cycles</brief_title>
  <official_title>Comparison of Blood Flow in the Arteriae Uterinae in Ovarian Stimulation Cycles for IVF/ICSI, in Hormonal Replacement Cycles and Natural Cycles for Frozen Embryo Transfer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Middle East Fertility Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IVI Middle East Fertility Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will measure the blood flow in the aa. uterinae in women, undergoing firstly
      ovarian stimulation for In-Vitro Fertilization (IVF) / Intracytoplasmic sperm injection
      (ICSI), in Hormonal Replacement cycles (HRT) and Natural cycles (NC) for Frozen Embryo
      Transfer (FET)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the influence of ovarian stimulation on the blood flow in the arteriae uterinae
      as well as whether there is an influence of the type of endometrial preparation for FET with
      either hormonal replacement therapy or natural cycle on the blood flow of the arteria uterina
      left / right
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the blood flow, calculated as Pulsatility Index (PI) and Resistance Index (RI), between the HRT- and the NC-FET cycles</measure>
    <time_frame>1 day</time_frame>
    <description>On the day of progesterone administration / progesterone rise. Quantitative continuous variable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Continuous quantitative variable measured as the differences between average PI value</measure>
    <time_frame>1 day</time_frame>
    <description>On the day of cycle start and the day of ovulation induction. Continuous quantitative variable measured in millimeters (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous quantitative variable measured as the differences between average RI value</measure>
    <time_frame>2 days</time_frame>
    <description>On the day of cycle start and the day of ovulation induction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thickness of the lining</measure>
    <time_frame>1 day</time_frame>
    <description>Continuous quantitative variable measured in millimeters (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of estradiol exposure</measure>
    <time_frame>1 day</time_frame>
    <description>Before the embryo transfer</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Endometrial Receptivity</condition>
  <arm_group>
    <arm_group_label>Artificial (HRT) Cycles</arm_group_label>
    <description>Commence estradiol tablets (E2) 4mg from day 2 or 3 of period for 3 days
Increase E2 to 6mg on day 4 of E2 treatment, according to clinician discretion based on endometrial thickness.
Transvaginal scan throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of a dominant follicle on the ovaries.
Serial measurements of serum LH (luteinizing hormone), estradiol and progesterone levels.
Initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 10 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance.
Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue E2 administration 6mg (3 tablets daily). Embryo transfer is scheduled 5 days following the initial initiation of progesterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spontaneous natural cycles</arm_group_label>
    <description>Day 2 of menses and throughout patients' natural cycle scans to monitor follicular growth.
Measurements of serum LH, estradiol and progesterone levels to determine ovulation.
The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter (Irani et al. 2017, Fatemi et al., 2010).
Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5nmol /L confirming ovulation (day 0) (Irani et al., 2017; Speroff et al.). This is considered as day 0 with initiation of vaginal progesterone 100mg at 22hrs that night. The following day (day 1) the patient increases progesterone administration to 100mg vaginally 8 hourly and continues until 7 weeks gestation as per clinic protocol. Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with primary / secondary infertility, who undergo an ovarian stimulation treatment
        for IVF/ICSI and subsequently are planned for FET with vitrified embryos, either as HRT-FET
        or as NC-FET
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who undergo ovarian stimulation in a Gonadotropin-Releasing-Hormone
             (GnRH)-antagonist protocol for IVF / ICSI

          -  Patients who have vitrified embryo(s)

          -  Preparation for FET either in HRT or NC cycle

        Exclusion Criteria:

          -  Poor responder according to Bologna criteria (Ferraretti et al.) as follows:

          -  At least two of the following three features must be present:

          -  (i) Advanced maternal age (≥40 years) or any other risk factor for poor ovarian
             reserve (POR);

          -  (ii) A previous POR (≤3 oocytes with a conventional stimulation protocol);

          -  (iii) An abnormal ovarian reserve test (i.e. antral follicle count (AFC) 5-7 follicles
             or anti-mullerian hormone (AMH) 0.5 -1.1 ng/ml).

          -  Uterine surgery for removal of fibroids (hysteroscopic, laparoscopic) or removal of
             uterine septum

          -  Endometriosis

          -  Asherman-Syndrome

          -  Previous cytotoxic treatment

          -  Previous radiation of the uterus / adnexal region

          -  Known hypertension

          -  Intake of Aspirin or similar medication which might influence the blood flow

          -  Status after tubal ligation

          -  Status after surgery in the adnexal region on 1 side
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Lawrenz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVI RMA Abu Dhabi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Lawrenz, PhD</last_name>
    <phone>+97126528000</phone>
    <phone_ext>1108</phone_ext>
    <email>barbara.lawrenz@ivirma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shieryl Digma, RN</last_name>
    <phone>+97126528000</phone>
    <phone_ext>1122</phone_ext>
    <email>shieryl.digma@ivirma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IVI Middle East Fertility Clinic</name>
      <address>
        <city>Abu Dhabi</city>
        <zip>60202</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Lawrenz, PhD</last_name>
      <phone>+97102 652 8000</phone>
      <phone_ext>1108</phone_ext>
      <email>barbara.lawrenz@ivirma.com</email>
    </contact>
    <contact_backup>
      <last_name>Shieryl Digma, RN</last_name>
      <phone>+97102 652 8000</phone>
      <phone_ext>1122</phone_ext>
      <email>shieryl.digma@ivirma.com</email>
    </contact_backup>
    <investigator>
      <last_name>Barbara Lawrenz, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <link>
    <url>http://www.medicalcity-iq.net/medlib/Clinical%20Gynecologic%20Endocrinology%20and%20Infertility.pdf</url>
    <description>Clinical Gynecologic Endocrinology and Infertility Part 1. Reproductive Physiology. Chapter 6: Regulation of the Menstrual Cycle. Ovulation : 212-216p.</description>
  </link>
  <reference>
    <citation>Abdalla HI, Brooks AA, Johnson MR, Kirkland A, Thomas A, Studd JW. Endometrial thickness: a predictor of implantation in ovum recipients? Hum Reprod. 1994 Feb;9(2):363-5.</citation>
    <PMID>8027298</PMID>
  </reference>
  <reference>
    <citation>Noyes N, Liu HC, Sultan K, Schattman G, Rosenwaks Z. Endometrial thickness appears to be a significant factor in embryo implantation in in-vitro fertilization. Hum Reprod. 1995 Apr;10(4):919-22.</citation>
    <PMID>7650143</PMID>
  </reference>
  <reference>
    <citation>Bakos O, Lundkvist O, Bergh T. Transvaginal sonographic evaluation of endometrial growth and texture in spontaneous ovulatory cycles--a descriptive study. Hum Reprod. 1993 Jun;8(6):799-806.</citation>
    <PMID>8345066</PMID>
  </reference>
  <reference>
    <citation>Tekay A, Martikainen H, Jouppila P. Comparison of uterine blood flow characteristics between spontaneous and stimulated cycles before embryo transfer. Hum Reprod. 1996 Feb;11(2):364-8.</citation>
    <PMID>8671225</PMID>
  </reference>
  <reference>
    <citation>Romero R. Giants in Obstetrics and Gynecology Series: A profile of Leon Speroff, MD. Am J Obstet Gynecol. 2017 Sep;217(3):263.e1-263.e8. doi: 10.1016/j.ajog.2017.05.056. Epub 2017 Jul 12.</citation>
    <PMID>28710912</PMID>
  </reference>
  <reference>
    <citation>Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011 Jul;26(7):1616-24. doi: 10.1093/humrep/der092. Epub 2011 Apr 19.</citation>
    <PMID>21505041</PMID>
  </reference>
  <results_reference>
    <citation>Irani M, Robles A, Gunnala V, Reichman D, Rosenwaks Z. Optimal parameters for determining the LH surge in natural cycle frozen-thawed embryo transfers. J Ovarian Res. 2017 Oct 16;10(1):70. doi: 10.1186/s13048-017-0367-7.</citation>
    <PMID>29037231</PMID>
  </results_reference>
  <results_reference>
    <citation>Fatemi HM, Kyrou D, Bourgain C, Van den Abbeel E, Griesinger G, Devroey P. Cryopreserved-thawed human embryo transfer: spontaneous natural cycle is superior to human chorionic gonadotropin-induced natural cycle. Fertil Steril. 2010 Nov;94(6):2054-8. doi: 10.1016/j.fertnstert.2009.11.036. Epub 2010 Jan 25.</citation>
    <PMID>20097333</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2019</study_first_posted>
  <last_update_submitted>May 15, 2019</last_update_submitted>
  <last_update_submitted_qc>May 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IVI Middle East Fertility Clinic</investigator_affiliation>
    <investigator_full_name>Barbara Lawrenz</investigator_full_name>
    <investigator_title>Scientific Director</investigator_title>
  </responsible_party>
  <keyword>progesterone</keyword>
  <keyword>endometrium</keyword>
  <keyword>blood flow</keyword>
  <keyword>estradiol</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03887728/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

